• Profile
Close

Cardiovascular morbidity and mortality in patients with type 2 diabetes using novel antidiabetic medicines as add-on therapy: An observational real-world study

BMJ Open Sep 16, 2021

Zerovnik S, Kos M, Locatelli I, et al. - When compared with dipeptidyl peptidase-4 inhibitors (DPP-4i) as an add-on therapy, sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) improved cardiovascular (CV) morbidity and mortality in individuals with type 2 diabetes (T2D). The findings of this study could be used to help clinicians choose the best add-on antidiabetic drug to reduce CV morbidity and death in patients with T2D.

  • Between June 2014 and June 2018, patients with T2D who received newly introduced DPP-4i (n = 3,817), GLP-1RA (n = 855) or SGLT2i (n = 2,851) add-on therapy.

  • When compared with DPP-4i, SGLT2i as an add-on therapy was linked with a lower risk of major adverse CV event (MACE) and CV mortality in the intention-to-treat analysis.

  • On-treatment research demonstrated a decreased risk of heart failure (HF) in patients starting SGLT2i.

  • GLP-1RA add-on therapy was related to a decreased MACE risk when compared with DPP-4i in the intention-to-treat analysis, but it had no effect on CV death or HF.

  • The findings of on-treatment analyses agreed with the findings of intention-to-treat analyses.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay